The price of Summit Therapeutics Inc (NASDAQ: SMMT) closed at $3.66 in the last session, down -9.06% from day before closing price of $4.03. On the day, 1310421 shares were traded.
Ratios:
We take a closer look at SMMT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.30 and its Current Ratio is at 9.30. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on March 26, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 27 ’24 when Zanganeh Mahkam bought 54,321 shares for $3.72 per share. The transaction valued at 201,874 led to the insider holds 24,923,800 shares of the business.
Zanganeh Mahkam bought 26,000 shares of SMMT for $96,720 on Mar 27 ’24. The Chief Executive Officer now owns 520,814 shares after completing the transaction at $3.72 per share. On Mar 26 ’24, another insider, Dhingra Ankur, who serves as the Chief Financial Officer of the company, bought 100,000 shares for $3.75 each. As a result, the insider paid 375,000 and bolstered with 354,958 shares of the company.
Stock Price History:
Over the past 52 weeks, SMMT has reached a high of $5.22, while it has fallen to a 52-week low of $1.30.
Shares Statistics:
A total of 701.66M shares are outstanding, with a floating share count of 82.98M. Insiders hold about 88.16% of the company’s shares, while institutions hold 4.65% stake in the company.
Earnings Estimates
The company has SMOT analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $3.67, with high estimates of $4.83 and low estimates of $2.44.
Analysts are recommending an EPS of between $Healthcare and $Technology for the fiscal current year, implying an average EPS of $Healthcare.
